CA2810632C - Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment - Google Patents

Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment Download PDF

Info

Publication number
CA2810632C
CA2810632C CA2810632A CA2810632A CA2810632C CA 2810632 C CA2810632 C CA 2810632C CA 2810632 A CA2810632 A CA 2810632A CA 2810632 A CA2810632 A CA 2810632A CA 2810632 C CA2810632 C CA 2810632C
Authority
CA
Canada
Prior art keywords
cells
isolated population
subject
syngeneic
party
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2810632A
Other languages
English (en)
French (fr)
Other versions
CA2810632A1 (en
Inventor
Yair Reisner
Assaf Lask
Eran Ophir
Noga Or-Geva
Adva Cohen
Ran Afik
Esther Bachar-Lustig
Yaki Eidelstein
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CA2810632A1 publication Critical patent/CA2810632A1/en
Application granted granted Critical
Publication of CA2810632C publication Critical patent/CA2810632C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2810632A 2010-09-08 2011-09-08 Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment Active CA2810632C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38071610P 2010-09-08 2010-09-08
US61/380,716 2010-09-08
PCT/IL2011/000727 WO2012032526A2 (en) 2010-09-08 2011-09-08 Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment

Publications (2)

Publication Number Publication Date
CA2810632A1 CA2810632A1 (en) 2012-03-15
CA2810632C true CA2810632C (en) 2020-06-02

Family

ID=45002090

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2810632A Active CA2810632C (en) 2010-09-08 2011-09-08 Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment

Country Status (15)

Country Link
US (2) US9421228B2 (enExample)
EP (1) EP2613801B1 (enExample)
JP (1) JP5977238B2 (enExample)
KR (1) KR101788826B1 (enExample)
CN (2) CN105907713A (enExample)
BR (1) BR112013005756A2 (enExample)
CA (1) CA2810632C (enExample)
ES (1) ES2589678T3 (enExample)
HU (1) HUE031063T2 (enExample)
IL (1) IL225102A (enExample)
MX (1) MX357746B (enExample)
PL (1) PL2613801T3 (enExample)
PT (1) PT2613801T (enExample)
SG (1) SG188473A1 (enExample)
WO (1) WO2012032526A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2506311C2 (ru) 2008-10-30 2014-02-10 Йеда Рисёрч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
JP5977238B2 (ja) 2010-09-08 2016-08-24 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 抗白血病／リンパ腫処置のための抗第三者セントラルメモリーｔ細胞の使用
CN103402541A (zh) 2011-01-10 2013-11-20 小利兰·斯坦福大学托管委员会 异源造血干细胞移植的增强
BR112014005355B1 (pt) 2011-09-08 2022-03-29 Yeda Research An Development Co., Ltd Células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença
JP6142142B2 (ja) * 2012-04-10 2017-06-07 株式会社リンフォテック メモリーｔ細胞を主成分とするリンパ球細胞群の製造方法
US11179448B2 (en) 2015-07-16 2021-11-23 Yeda Research And Development Co. Ltd. Genetically modified anti-third party central memory T cells and use of same in immunotherapy
WO2018002924A1 (en) * 2016-06-27 2018-01-04 Yeda Research And Development Co. Ltd. Veto cells generated from memory t cells
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
IL268126B2 (en) 2017-01-18 2024-02-01 Yeda Res & Dev Genetically engineered Veto cells and their uses in immunotherapy
AU2018234827B2 (en) * 2017-03-15 2024-04-04 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
IL292722A (en) * 2019-11-05 2022-07-01 Yeda res & development co ltd Use of veto cells in treatment of t cell mediated autoimmune diseases
CA3160296A1 (en) * 2019-11-05 2021-05-14 Yeda Research And Development Co. Ltd. Use of veto cells for the treatment of sickle cell disease

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5599703A (en) 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
WO2000039294A1 (en) 1998-12-24 2000-07-06 Novartis Ag Porcine cells incapable of expressing cd40 antigen, for xenotransplantation
US6544506B2 (en) 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
AU5340001A (en) 2000-04-11 2001-10-23 Univ Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
SI1935427T1 (en) 2000-07-03 2018-05-31 Bristol-Myers Squibb Company USE OF HEATED CTLA4 MUTANT MOLECULES
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
EP1337152A4 (en) 2000-11-30 2004-08-11 Yeda Res & Dev METHODS OF USING CULTURED T CELLS THAT DO NOT INDUCE HOST Graft Reaction (GVHD) TO TREAT DISEASE
PL204899B1 (pl) 2001-05-23 2010-02-26 Bristol Myers Squibb Co Zastosowanie rozpuszczalnej zmutowanej cząsteczki CTLA4
US20030147859A1 (en) 2001-06-18 2003-08-07 Yair Reisner Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance
NZ545314A (en) 2003-08-04 2009-03-31 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble CTLA4 molecule
CA2560919A1 (en) 2004-03-26 2005-10-06 Pfizer Products Inc. Uses of anti-ctla-4 antibodies
WO2006041763A1 (en) 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
ES2601896T3 (es) 2004-11-24 2017-02-16 Fred Hutchinson Cancer Research Center Procedimientos de uso de la IL-21 en la inmunoterapia adoptiva y la identificación de antígenos tumorales
SI1868635T1 (sl) 2005-04-06 2017-07-31 Bristol-Myers Squibb Company Postopki za zdravljenje imunskih motenj, povezanih s transplantacijo presadkov s topnimi mutiranimi CTLA4 molekulami
EP2514315A3 (en) * 2005-08-24 2012-11-07 Yeda Research and Development Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
US20110165639A1 (en) * 2008-08-15 2011-07-07 Brijen Biotech, Llc Refinery process to produce biofuels and bioenergy products from home and municipal solid waste
US8200915B2 (en) 2008-08-22 2012-06-12 Cadence Design Systems, Inc. Management of very large streaming data sets for efficient writes and reads to and from persistent storage
RU2506311C2 (ru) 2008-10-30 2014-02-10 Йеда Рисёрч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
JP2013540731A (ja) 2010-09-08 2013-11-07 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 安定かつ長期間の生着のための免疫抑制薬物組合せ
JP5977238B2 (ja) 2010-09-08 2016-08-24 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 抗白血病／リンパ腫処置のための抗第三者セントラルメモリーｔ細胞の使用
BR112014005355B1 (pt) 2011-09-08 2022-03-29 Yeda Research An Development Co., Ltd Células t de memória central anti-terceiro, métodos de produção e uso das mesmas em transplante e tratamento de doença

Also Published As

Publication number Publication date
KR20140030094A (ko) 2014-03-11
KR101788826B1 (ko) 2017-10-20
PL2613801T3 (pl) 2016-12-30
MX357746B (es) 2018-07-23
SG188473A1 (en) 2013-05-31
BR112013005756A2 (pt) 2018-12-26
PT2613801T (pt) 2016-09-12
CN103282047A (zh) 2013-09-04
EP2613801A2 (en) 2013-07-17
EP2613801B1 (en) 2016-06-08
WO2012032526A3 (en) 2012-05-18
ES2589678T3 (es) 2016-11-15
CN105907713A (zh) 2016-08-31
MX2013002668A (es) 2013-09-26
CN103282047B (zh) 2016-08-24
IL225102A (en) 2017-05-29
WO2012032526A2 (en) 2012-03-15
HUE031063T2 (en) 2017-06-28
JP2013537187A (ja) 2013-09-30
US20130171108A1 (en) 2013-07-04
JP5977238B2 (ja) 2016-08-24
US9421228B2 (en) 2016-08-23
US20160354410A1 (en) 2016-12-08
CA2810632A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
US12133866B2 (en) Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
EP2613801B1 (en) Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
US9738872B2 (en) Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
CN115175688A (zh) 在数个t细胞介导的自身免疫性疾病的治疗中的数个否决细胞的用途
HK1187528B (en) Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
HK1200099B (en) Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160907

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240904

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240904

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240904

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250930

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250930

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260224